Logo

Samsung Bioepis Receives the US FDA's Approval for Multi-Dose Vial of Ontruzant (biosimilar- trastuzumab)

Share this

Samsung Bioepis Receives the US FDA's Approval for Multi-Dose Vial of Ontruzant (biosimilar- trastuzumab)

Shots:

  • The US FDA has approved the 420 mg multi-dose vial of Ontruzant (trastuzumab-dttb)- a biosimilar referencing Herceptin (trastuzumab) and will be marketed & distributed by Merck in the US
  • On Feb 05- 2020- Merck has announced the spin-off its biosimilar business and will continue to support the commercialization of Ontruzant until the spinoff- which is anticipated to be held in H1’21
  • Ontruzant (150 mg- single-dose vial) is an approved therapy for HER2-overexpressing BC- mBC and mGC or gastroesophageal junction adenocarcinoma in patients with prior treatment for metastatic disease

Click here ­to­ read full press release/ article 

 Ref: Samsung Bioepis | Image: Samsung Bioepis


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions